vs

Side-by-side financial comparison of CAVA GROUP, INC. (CAVA) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

CAVA GROUP, INC. is the larger business by last-quarter revenue ($280.6M vs $207.3M, roughly 1.4× Ultragenyx Pharmaceutical Inc.). CAVA GROUP, INC. runs the higher net margin — 6.5% vs -62.0%, a 68.6% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 20.2%). CAVA GROUP, INC. produced more free cash flow last quarter ($19.2M vs $-100.8M).

Cava, also referred to as Cava Grill, is an American Mediterranean fast casual restaurant chain with locations across the United States. Cava is owned by the publicly traded Cava Group, which purchased Zoës Kitchen in August 2018. The combined company is the largest restaurant operator in the Mediterranean category in the U.S. restaurant industry. Cava also produces a line of Mediterranean dips, spreads, and dressings that are sold in grocery stores across the US. As of May 2023, all Zoës Kit...

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

CAVA vs RARE — Head-to-Head

Bigger by revenue
CAVA
CAVA
1.4× larger
CAVA
$280.6M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+5.7% gap
RARE
25.9%
20.2%
CAVA
Higher net margin
CAVA
CAVA
68.6% more per $
CAVA
6.5%
-62.0%
RARE
More free cash flow
CAVA
CAVA
$120.0M more FCF
CAVA
$19.2M
$-100.8M
RARE

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
CAVA
CAVA
RARE
RARE
Revenue
$280.6M
$207.3M
Net Profit
$18.4M
$-128.6M
Gross Margin
Operating Margin
7.0%
-54.7%
Net Margin
6.5%
-62.0%
Revenue YoY
20.2%
25.9%
Net Profit YoY
-7.0%
3.5%
EPS (diluted)
$0.16
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CAVA
CAVA
RARE
RARE
Q4 25
$207.3M
Q3 25
$280.6M
$159.9M
Q2 25
$331.8M
$166.5M
Q1 25
$139.3M
Q4 24
$164.6M
Q3 24
$233.5M
$139.5M
Q2 24
$259.0M
$147.0M
Q1 24
$108.8M
Net Profit
CAVA
CAVA
RARE
RARE
Q4 25
$-128.6M
Q3 25
$18.4M
$-180.4M
Q2 25
$25.7M
$-115.0M
Q1 25
$-151.1M
Q4 24
$-133.2M
Q3 24
$19.7M
$-133.5M
Q2 24
$14.0M
$-131.6M
Q1 24
$-170.7M
Gross Margin
CAVA
CAVA
RARE
RARE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
26.7%
Q2 24
25.2%
Q1 24
Operating Margin
CAVA
CAVA
RARE
RARE
Q4 25
-54.7%
Q3 25
7.0%
-106.9%
Q2 25
4.7%
-64.8%
Q1 25
-102.6%
Q4 24
-74.3%
Q3 24
6.9%
-94.6%
Q2 24
3.6%
-79.1%
Q1 24
-151.9%
Net Margin
CAVA
CAVA
RARE
RARE
Q4 25
-62.0%
Q3 25
6.5%
-112.8%
Q2 25
7.7%
-69.0%
Q1 25
-108.5%
Q4 24
-80.9%
Q3 24
8.5%
-95.7%
Q2 24
5.4%
-89.5%
Q1 24
-156.8%
EPS (diluted)
CAVA
CAVA
RARE
RARE
Q4 25
$-1.28
Q3 25
$0.16
$-1.81
Q2 25
$0.22
$-1.17
Q1 25
$-1.57
Q4 24
$-1.34
Q3 24
$0.17
$-1.40
Q2 24
$0.12
$-1.52
Q1 24
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CAVA
CAVA
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$290.2M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$750.7M
$-80.0M
Total Assets
$1.3B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CAVA
CAVA
RARE
RARE
Q4 25
$421.0M
Q3 25
$290.2M
$202.5M
Q2 25
$289.4M
$176.3M
Q1 25
$127.1M
Q4 24
$174.0M
Q3 24
$343.7M
$150.6M
Q2 24
$329.1M
$480.7M
Q1 24
$112.3M
Stockholders' Equity
CAVA
CAVA
RARE
RARE
Q4 25
$-80.0M
Q3 25
$750.7M
$9.2M
Q2 25
$726.2M
$151.3M
Q1 25
$144.2M
Q4 24
$255.0M
Q3 24
$595.4M
$346.8M
Q2 24
$580.8M
$432.4M
Q1 24
$140.3M
Total Assets
CAVA
CAVA
RARE
RARE
Q4 25
$1.5B
Q3 25
$1.3B
$1.2B
Q2 25
$1.2B
$1.3B
Q1 25
$1.3B
Q4 24
$1.5B
Q3 24
$1.0B
$1.5B
Q2 24
$1.0B
$1.6B
Q1 24
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CAVA
CAVA
RARE
RARE
Operating Cash FlowLast quarter
$60.3M
$-99.8M
Free Cash FlowOCF − Capex
$19.2M
$-100.8M
FCF MarginFCF / Revenue
6.8%
-48.6%
Capex IntensityCapex / Revenue
14.7%
0.5%
Cash ConversionOCF / Net Profit
3.28×
TTM Free Cash FlowTrailing 4 quarters
$49.3M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CAVA
CAVA
RARE
RARE
Q4 25
$-99.8M
Q3 25
$60.3M
$-91.4M
Q2 25
$38.6M
$-108.3M
Q1 25
$-166.5M
Q4 24
$-79.3M
Q3 24
$48.9M
$-67.0M
Q2 24
$38.4M
$-77.0M
Q1 24
$-190.7M
Free Cash Flow
CAVA
CAVA
RARE
RARE
Q4 25
$-100.8M
Q3 25
$19.2M
$-92.7M
Q2 25
$2.7M
$-110.7M
Q1 25
$-167.8M
Q4 24
$-79.5M
Q3 24
$22.7M
$-68.6M
Q2 24
$4.7M
$-79.0M
Q1 24
$-193.9M
FCF Margin
CAVA
CAVA
RARE
RARE
Q4 25
-48.6%
Q3 25
6.8%
-58.0%
Q2 25
0.8%
-66.5%
Q1 25
-120.5%
Q4 24
-48.3%
Q3 24
9.7%
-49.2%
Q2 24
1.8%
-53.7%
Q1 24
-178.2%
Capex Intensity
CAVA
CAVA
RARE
RARE
Q4 25
0.5%
Q3 25
14.7%
0.8%
Q2 25
10.8%
1.5%
Q1 25
1.0%
Q4 24
0.1%
Q3 24
11.2%
1.2%
Q2 24
13.0%
1.4%
Q1 24
3.0%
Cash Conversion
CAVA
CAVA
RARE
RARE
Q4 25
Q3 25
3.28×
Q2 25
1.50×
Q1 25
Q4 24
Q3 24
2.48×
Q2 24
2.74×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CAVA
CAVA

Restaurant Revenue$278.2M99%
Rewards$2.8M1%
CPG Revenue And Other$2.4M1%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons